Matt LiuTai Chung TsengDae Won JunMing Lun YehHuy TrinhGrace L.H. WongChien Hung ChenCheng Yuan PengSung Eun KimHyunwoo OhMin Sun KwakMichael CheungHidenori ToyodaYao Chun HsuJae Yoon JeongEileen L. YoonTeerapat UngtrakulJian ZhangQing XieSang Bong AhnMasaru EnomotoJae Jun ShimChris CunninghamSoung Won JeongYong Kyun ChoEiichi OgawaRui HuangDong Hyun LeeHirokazu TakahashiPei Chien TsaiChung Feng HuangChia Yen DaiCheng Hao TsengSatoshi YasudaRitsuzo KozukaJiayi LiChristopher WongClifford C. WongChangqing ZhaoJoseph HoangYuichiro EguchiChao WuYasuhito TanakaEd GaneTawesak TanwandeeRamsey CheungMan Fung YuenHyo Suk LeeMing Lung YuJia Horng KaoHwai I. YangMindie H. NguyenOsaka Metropolitan UniversityHanyang University HospitalSiriraj HospitalMassey University WellingtonGood Gang-An HospitalAcademia Sinica, Genomics Research CenterE-Da HospitalShanghai Jiao Tong University School of MedicineInje University Paik HospitalChang Gung University College of MedicineKaohsiung Medical University Chung-Ho Memorial HospitalNational Taiwan University HospitalSaga University HospitalChina Medical University HospitalEulji University, School of MedicinePalo Alto Medical FoundationKyung Hee Medical CenterSoonchunhyang University, College of MedicineChulabhorn Royal AcademyKyushu University HospitalSKKU School of MedicineStanford University Medical CenterUniversity of WashingtonAuckland City HospitalShanghai University of Traditional Chinese MedicineThe University of Hong KongHallym University, College of MedicineMedical School of Nanjing UniversityNagoya City University Graduate School of Medical SciencesChinese University of Hong KongOgaki Municipal HospitalSeoul National University College of MedicineWong ClinicsNational Medical CenterChinese HospitalSan Jose Gastroenterology2022-08-042022-08-042021-02-01Hepatology International. Vol.15, No.1 (2021), 71-8119360541193605332-s2.0-85098964636https://repository.li.mahidol.ac.th/handle/123456789/78486Background: Increasing hepatitis-related mortality has reignited interest to fulfill the World Health Organization’s goal of viral hepatitis elimination by 2030. However, economic barriers have enabled only 28% of countries to implement countermeasures. Given the high disease burden among Asians, we aimed to present age, sex, disease activity and treatment-specific annual progression rates among Asian chronic hepatitis B (CHB) patients to inform health economic modeling efforts and cost-effective public health interventions. Methods: We analyzed 18,056 CHB patients from 36 centers across the U.S. and seven countries/regions of Asia Pacific (9530 treated; 8526 untreated). We used Kaplan–Meier methods to estimate annual incidence of cirrhosis and hepatocellular carcinoma (HCC). Active disease was defined by meeting the APASL treatment guideline criteria. Results: Over a median follow-up of 8.55 years, there were 1178 incidences of cirrhosis and 1212 incidences of HCC (297 without cirrhosis, 915 with cirrhosis). Among the 8526 untreated patients (7977 inactive, 549 active), the annual cirrhosis and HCC incidence ranged from 0.26% to 1.30% and 0.04% to 3.80% in inactive patients, and 0.55 to 4.05% and 0.19 to 6.03% in active patients, respectively. Of the 9530 treated patients, the annual HCC rates ranged 0.03–1.57% among noncirrhotic males and 2.57–6.93% among cirrhotic males, with lower rates for females. Generally, transition rates increased with age, male sex, the presence of fibrosis/cirrhosis, and active disease and/or antiviral treatment. Conclusion: Using data from a large and diverse real-world cohort of Asian CHB patients, the study provided detailed annual transition rates to inform practice, research and public health planning.Mahidol UniversityMedicineArticleSCOPUS10.1007/s12072-020-10113-2